Mar 15, 2012 Issue
Evaluation and Treatment of the Suicidal Patient [Article]

Evaluation and treatment of a suicidal patient are challenging tasks for the physician. Because no validated predictive tools exist, clinical judgment guides the decision-making process. Although there is insufficient evidence to support routine screening, evidence shows that asking high-risk patien...

Dec 1, 2011 Issue
Personality Disorders: Review and Clinical Application in Daily Practice [Article]

Personality disorders have been documented in approximately 9 percent of the general U.S. population. Psychotherapy, pharmacotherapy, and brief interventions designed for use by family physicians can improve the health of patients with these disorders. Personality disorders are classified into clust...

Feb 1, 2011 Issue
Clozapine vs. Other Atypical Antipsychotics for Schizophrenia [Cochrane for Clinicians]

Although further trials are needed, there is some evidence that clozapine is slightly more effective than risperidone (Risperdal). Fewer participants taking clozapine dropped out of studies because of lack of effectiveness compared with those taking risperidone (number needed to treat = 11; 95% conf...

Sep 1, 2010 Issue
Neuropsychological Evaluation in Primary Care [Article]

Referring a patient to a neuropsychologist for evaluation provides a level of rigorous assessment of brain function that often cannot be obtained in other ways. The neuropsychologist integrates information from the patient’s medical history, laboratory tests, and imaging studies; an in-depth intervi...

Aug 15, 2010 Issue
Schizophrenia (Maintenance Treatment) [Clinical Evidence Handbook]

What are the effects of treatments to reduce relapse rates in persons with schizophrenia? What are the effects of interventions in persons with schizophrenia who are resistant to standard antipsychotics? What are the effects of interventions to improve adherence to medication?

Jun 1, 2010 Issue
Aripiprazole vs. Other Atypical Antipsychotics for Schizophrenia [Cochrane for Clinicians]

Aripiprazole is less effective in treating schizophrenia than olanzapine (Zyprexa), but has fewer metabolic and sedative adverse effects. There is no difference in effectiveness between aripiprazole and risperidone (Risperdal); however, aripiprazole may be associated with less dystonia, smaller incr...

May 1, 2010 Issue
Risperidone vs. Placebo for Schizophrenia [Cochrane for Clinicians]

Compared with placebo, risperidone improves symptoms based on some disease-specific symptom scores for schizophrenia. However, it does not appear to improve symptoms on a more important Clinical Global Impression scale.

May 1, 2010 Issue
Practical Considerations for Determining Patient Capacity and Consent [Curbside Consultation]

The core issue is whether the patient possesses decisional capacity and can provide informed consent.

Mar 1, 2010 Issue
Use of Atypical Antipsychotics in Children: Balancing Safety and Effectiveness [Editorials]

Mar 1, 2010 Issue
Adverse Effects of Antipsychotic Medications [Article]

The use of antipsychotic medications entails a difficult trade-off between the benefit of alleviating psychotic symptoms and the risk of troubling, sometimes life-shortening adverse effects. There is more variability among specific antipsychotic medications than there is between the first- and secon...

Pages: Previous 1 2 3 4 5 6 7 8 9 Next

Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now